Format

Send to

Choose Destination
Drug Discov Today. 2019 Jan;24(1):272-278. doi: 10.1016/j.drudis.2018.08.010. Epub 2018 Aug 17.

Advancing precision medicine with personalized drug screening.

Author information

1
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892-3375, USA.
2
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-3375, USA.
3
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892-3375, USA. Electronic address: wzheng@mail.nih.gov.

Abstract

Personalized drug screening (PDS) of approved drug libraries enables rapid development of specific small-molecule therapies for individual patients. With a multidisciplinary team including clinicians, researchers, ethicists, informaticians and regulatory professionals, patient treatment can be optimized with greater efficacy and fewer adverse effects by using PDS as an approach to find remedies. In addition, PDS has the potential to rapidly identify therapeutics for a patient suffering from a disease without an existing therapy. From cancer to bacterial infections, we review specific maladies addressed with PDS campaigns. We predict that PDS combined with personal genomic analyses will contribute to the development of future precision medicine endeavors.

PMID:
30125678
PMCID:
PMC6372320
[Available on 2020-01-01]
DOI:
10.1016/j.drudis.2018.08.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center